Research Project Introduction

STACCATO_logo.png

STACCATO 

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

The STACCATO trial is a double-masked, randomized, placebo-controlled clinical study comparing oral valganciclovir and topical 2% ganciclovir for the treatment of PCR-proven CMV anterior uveitis. The study aims to determine which antiviral approach most effectively reduces CMV viral load in anterior chamber aqueous fluid.

Principal Investigator

John Gonzales, MD

Study Design

Multicenter, block-randomized, double-masked, placebo-controlled trial.

Trial Details & Objectives

  • Study Arms: Oral valganciclovir, topical 2% ganciclovir, and placebo.
  • Primary Outcome: Percentage reduction in CMV viral load in anterior chamber aqueous fluid after 7 days.
  • Secondary Outcomes: Time to clinical quiescence and the effect of pre-enrollment topical corticosteroid use on initial viral load.
  • Hypothesis: Oral valganciclovir will provide the greatest reduction in CMV viral load.

Context: CMV Anterior Uveitis Treatment

Cytomegalovirus anterior uveitis is an important cause of chronic, recurrent, unilateral hypertensive anterior uveitis in immunocompetent individuals. Diagnosis typically requires detection of CMV DNA in aqueous humor obtained through anterior chamber paracentesis.

Current management may include topical antiviral therapy, systemic antiviral therapy, or other individualized approaches. By directly comparing oral valganciclovir, topical 2% ganciclovir, and placebo, the STACCATO trial helps address an important evidence gap in determining how best to control viral replication and inflammation.

Why This Study Matters

STACCATO is designed to generate evidence that can guide treatment decisions for CMV anterior uveitis, particularly when clinicians must choose between topical and systemic antiviral strategies.

Clinical Relevance

Better antiviral control may reduce recurrent inflammation, elevated intraocular pressure, and long-term complications associated with CMV anterior uveitis.

STACCATO Study Sites

An international, multi-site randomized clinical trial across the United States, Taiwan, and Thailand.

πŸ”’ How to access your site documents

1 Find your site below and click Site Documents.
2 Enter your site password. Each site has its own password, sent privately.
3 Click Download All, then open the ZIP with the same password.

Don't have a password or need help? Contact John Gonzales, MD, Principal Investigator: [email protected]

United States
UCSF Proctor Foundation logo
JohnsFace.png
UCSF β€” Proctor Foundation
San Francisco, California

John Gonzales, MD

Principal Investigator

Coordinating Center

UCLA Stein Eye Institute logo
Edmund Tsui
UCLA β€” Stein Eye Institute
Los Angeles, California

Edmund Tsui, MD, MS

Site Principal Investigator

Taiwan
chuanggugn hospital logo
 Dr. Yi-Hsing (Linda) Chenζž—ε£ι•·εΊšη΄€εΏ΅ι†«ι™’ηœΌη§‘ιƒ¨ηš„ι™³ζ€‘ζι†«εΈ«
Linkou Chang Gung Memorial Hospital

ζž—ε£ι•·εΊšη΄€εΏ΅ι†«ι™’

Taoyuan

Yi-Hsing (Linda) Chen, MD, PhD

Site Principal Investigator

Yih-Shiou Hwang, MD, PhD

Yih-Shiou Hwang, MD, PhD

Co-Investigator

Thailand
Logo_of_the_Faculty_of_Medicine,_Chulalongkorn_University.jpg
Assoc. Prof. Thanapong Somkijrungroj, MD
Chulalongkorn University
King Chulalongkorn Memorial Hospital, Bangkok

Assoc. Prof. Thanapong Somkijrungroj, MD

Site PI Β· Head, Uveitis Unit

Khon Kaen University logo
Wipada Laovirojjanakul, MD.jpg
Khon Kaen University
Khon Kaen

Wipada Laovirojjanakul, MD

Site Principal Investigator

Chingmailogo
Prof. Kessara Pathanapitoon, MD, PhD.jpg
Chiang Mai University
Chiang Mai

Prof. Kessara Pathanapitoon, MD, PhD

Site Principal Investigator

Asst. Prof. Dr. Atitaya Apivatthakakul

Asst. Prof. Atitaya Apivatthakakul, MD, PhD

Co-Investigator Β· Uveitis & Retina

Learn More About the Trial

View the official ClinicalTrials.gov record for study details, eligibility criteria, study arms, and outcome measures.

View STACCATO Trial: NCT07513623